7-24 | A simplified model of care for hepatitis C patients in Cambodia has shown outstanding results with 97% of patients cured from the disease in just three months, Médecins Sans Frontières (MSF) said. Since 2016, MSF has treated more than 13,000 patients in Cambodia’s capital, Phnom Penh, through a simpler and more affordable model of care, a crucial requirement to widen treatment access and eliminate hepatitis C in the country. Hepatitis C, a blood-borne virus that attacks the liver, is endemic in Cambodia.
6-4 | Arish was born in October 2018 at the MSF birthing unit in Chaman District Headquarter (DHQ) Hospital, Balochistan. He was discharged in good health. Just four days after his birth, however, he was back at the hospital in severe distress. His mother, Malaika, was unable to produce enough milk to feed him. “When I couldn’t feed him, I gave him green tea instead.
6-19 | Affordable generic versions from China could save millions of people’s lives Médecins Sans Frontières (MSF) today filed a legal patent challenge at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent granted to US pharmaceutical corporation Gilead Sciences for the oral hepatitis C medicine velpatasvir.
3-5 | Turn into this narrow side street from a traffic-choked avenue in Phnom Penh, the capital of Cambodia, and the volume suddenly drops. Removed from the honking tuk-tuks and bathing in shade, a bright mural welcomes visitors to the drop-in centre of a charity, called ‘Mith Samlanh’.
MSF challenges Gilead’s patent application for hepatitis C combination treatment in China, to bring down prices
12-18 | Gilead recently launched one of these drugs for $100/pill in China Médecins Sans Frontières (MSF) has filed a legal patent challenge in China against US pharmaceutical corporation Gilead’s patent application for the combination of two crucial oral hepatitis C medicines, sofosbuvir and velpatasvir. This combination is the first direct-acting antiviral (DAA) treatment to be registered for use against all genotypes* of the disease.